Table 3.
Change in hepatic function parameters from baseline at 2 and 6 months of antituberculosis treatment
| Control group Median (IQR) (2 or 6 months value Minus baseline value) | Test group Median (IQR) (2 or 6 months value Minus baseline value) | P‐value | |
|---|---|---|---|
| Month 2 | |||
| AST (U/L) | 33.45 (18.73–42.88) | −12.6 (−30.2 to 4.7) | <0.001a |
| ALT (U/L) | 58.75 (48.68–73.98) | −12.5 (−17.6 to 6.5) | <0.001a |
| ALP (U/L) | 14.1 (−2.8 to 35.88) | −15.1 (−27.2 to 4.1) | <0.001a |
| T_Bil (mmol/L) | 3.2 (0–10.1) | −2.6 (−3.5 to 1.5) | <0.001a |
| Month 6 | |||
| AST (U/L) | 4.75 (−11.93−16.33) | −4.7 (−33.5 to 8.9) | 0.313 |
| ALT (U/L) | −0.5 (−10.6 to 25.4) | 10.8 (−11.6 to 55.3) | 0.531 |
| ALP (U/L) | 8.3 (−30.3–25.43) | −2.2 (−52.6 to 17.9) | 0.454 |
| T_Bil (mmol/L) | 0.15 (−2.78 to 1.3) | −1.1 (−3.7 to 0.5) | 0.918 |
A positive median value of hepatic parameter shows an increase from baseline value, while a negative value indicate a decrease from baseline value.
a
Mann Whitney U test (Significant); IQR, Interquartile range.